RxDoctor Payments Data

James Webb

Podiatrist · Bartlesville, OKNPI 1679561385

Payments from drug & device makers

What this record shows

The money is spread across several categories — education (49.5%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Pylant Medical at 37.4% of the total. Reporting peaked in 2019 at $1,647 and has fallen 77.7% since, to $367 in 2025.

$2,602in general payments, 2019–2025

Across 61 payments — averaging $42.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pylant Medical$972
  • Stryker$432
  • DJO, LLC$224
  • Spinefrontier, Inc.$187
  • Smith+Nephew$186
  • Zyla Life Sciences, Inc.$159
  • plus $441 from 9 others

What the payments were for

  • Consulting fees$1004%
  • Food & beverage$1,21347%
  • Education$1,28850%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pylant Medical1$972
Stryker3$432
DJO, LLC3$224
Spinefrontier, Inc.1$187
Smith+Nephew9$186
Zyla Life Sciences, Inc.24$159
Comsort, Inc1$100
Rikco International, LLC2$88
Merck7$67
Amgen(2 entities)3$42
Organogenesis Inc.2$39
Nevro Corp.2$35
Johnson & Johnson1$34
Paratek Pharmaceuticals, Inc.1$22
KCI USA, Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,602 in reported general payments places this provider in the 60th percentile of 54 podiatrist providers in Oklahoma.

See all podiatrist providers in Oklahoma

Medicare billing

Part B allowed, 2024
$112,800
Medicare patients
425
Services billed
1,432

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.14$4,476
Diclofenac Sodium209$1,741
Pregabalin108$1,432
Amitriptyline Hcl78$752
Duloxetine Hcl43$485
Ropinirole Hcl24$429
Gabapentin34$426
Mupirocin61$408
Terbinafine Hcl20$407
Celecoxib14$390
Ketoconazole12$376
Methylprednisolone46$310
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav26$282
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen24$156
Azithromycin30$148

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$186$4,47614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 54 podiatrist providers in Oklahoma.

Other podiatrist in Bartlesville

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →